HK1077218A1 - Oral solid solution formulation of a poorly water-soluble active substance - Google Patents

Oral solid solution formulation of a poorly water-soluble active substance

Info

Publication number
HK1077218A1
HK1077218A1 HK05109356A HK05109356A HK1077218A1 HK 1077218 A1 HK1077218 A1 HK 1077218A1 HK 05109356 A HK05109356 A HK 05109356A HK 05109356 A HK05109356 A HK 05109356A HK 1077218 A1 HK1077218 A1 HK 1077218A1
Authority
HK
Hong Kong
Prior art keywords
active substance
solid solution
poorly water
oral solid
soluble active
Prior art date
Application number
HK05109356A
Other languages
English (en)
Inventor
Henricus R M Gorissen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of HK1077218A1 publication Critical patent/HK1077218A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05109356A 2002-02-14 2005-10-20 Oral solid solution formulation of a poorly water-soluble active substance HK1077218A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075623 2002-02-14
PCT/EP2003/050014 WO2003068266A1 (en) 2002-02-14 2003-02-11 Oral solid solution formulation of a poorly water-soluble active substance

Publications (1)

Publication Number Publication Date
HK1077218A1 true HK1077218A1 (en) 2006-02-10

Family

ID=27619166

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05109356A HK1077218A1 (en) 2002-02-14 2005-10-20 Oral solid solution formulation of a poorly water-soluble active substance

Country Status (25)

Country Link
US (2) US20050008697A1 (ja)
EP (1) EP1476196B1 (ja)
JP (1) JP2005517041A (ja)
KR (1) KR101014545B1 (ja)
CN (1) CN1273194C (ja)
AR (1) AR038681A1 (ja)
AT (1) ATE345817T1 (ja)
AU (1) AU2003208713B2 (ja)
BR (1) BR0307278A (ja)
CA (1) CA2472744A1 (ja)
DE (1) DE60309839T2 (ja)
DK (1) DK1476196T3 (ja)
ES (1) ES2277635T3 (ja)
HK (1) HK1077218A1 (ja)
HR (1) HRP20040613A2 (ja)
IL (2) IL162883A0 (ja)
MX (1) MXPA04007852A (ja)
NO (1) NO20043832L (ja)
PL (1) PL370452A1 (ja)
PT (1) PT1476196E (ja)
RU (1) RU2314811C2 (ja)
SI (1) SI1476196T1 (ja)
UA (1) UA79267C2 (ja)
WO (1) WO2003068266A1 (ja)
ZA (1) ZA200405608B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
EA014898B1 (ru) * 2006-06-16 2011-02-28 Солвей Фармасьютикалс Б.В. Пероральная фармацевтическая композиция из активного вещества, плохо растворимого в воде
AU2007263016A1 (en) * 2006-06-22 2007-12-27 Panacea Biotec Ltd. Oral pharmaceutical composition of a poorly water-soluble active substance
EP2037897B1 (en) * 2006-07-06 2011-03-30 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
US20080181959A1 (en) * 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20120034297A1 (en) 2010-08-04 2012-02-09 Gruenenthal Gmbh Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
LT2600839T (lt) * 2010-08-04 2018-03-26 GrĆ¼nenthal GmbH Vaistinė dozavimo forma, apimanti 6'-fluor-(n-metil- arba n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-aminą
CN107735080B (zh) * 2015-07-03 2020-10-23 浙江海正药业股份有限公司 一种人参皂苷c-k口服固体制剂及其制备方法
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
IL283450B1 (en) * 2018-11-30 2024-02-01 Chemocentryx Inc Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3359167A (en) * 1965-07-22 1967-12-19 Pfizer & Co C Vitamin a compositions
US4325970A (en) * 1980-10-09 1982-04-20 Hoffmann-La Roche Inc. 15-Acetyl-prostaglandins
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
EP0988046B1 (en) * 1997-01-30 2004-09-15 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin a
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions

Also Published As

Publication number Publication date
ES2277635T3 (es) 2007-07-16
ZA200405608B (en) 2005-06-24
US20110086844A1 (en) 2011-04-14
WO2003068266A1 (en) 2003-08-21
RU2004127457A (ru) 2005-04-20
IL162883A (en) 2009-05-04
JP2005517041A (ja) 2005-06-09
AU2003208713A1 (en) 2003-09-04
HRP20040613A2 (en) 2005-04-30
AR038681A1 (es) 2005-01-26
DE60309839D1 (de) 2007-01-04
AU2003208713B9 (en) 2003-09-04
ATE345817T1 (de) 2006-12-15
AU2003208713B2 (en) 2007-10-18
CN1273194C (zh) 2006-09-06
RU2314811C2 (ru) 2008-01-20
PL370452A1 (en) 2005-05-30
BR0307278A (pt) 2004-12-28
KR20040085193A (ko) 2004-10-07
KR101014545B1 (ko) 2011-02-16
US20050008697A1 (en) 2005-01-13
DK1476196T3 (da) 2007-03-05
MXPA04007852A (es) 2004-10-15
DE60309839T2 (de) 2007-03-15
NO20043832L (no) 2004-09-13
CA2472744A1 (en) 2003-08-21
SI1476196T1 (sl) 2007-04-30
CN1633307A (zh) 2005-06-29
EP1476196B1 (en) 2006-11-22
EP1476196A1 (en) 2004-11-17
PT1476196E (pt) 2007-02-28
IL162883A0 (en) 2005-11-20
UA79267C2 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
HK1077218A1 (en) Oral solid solution formulation of a poorly water-soluble active substance
TWI319319B (en) New solid pharmaceutical formulations comprising telmisartan and preparation thereof
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
IL221199A (en) A fragrance-containing drug
HK1070585A1 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2003252299A8 (en) Novel physiologically active substance
SI1608362T1 (sl) Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
AU2003215245A8 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1750680A4 (en) FORMULATIONS OF WATER-SOLUBLE AGENTS COATED WITH SLOW RELEASE COMPRESSION
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
EP1496863A4 (en) ELABORATION AND USE OF STABLE FORMULATION OF ALLOSTERICALLY EFFECTIVE COMPOUNDS
HUP0500638A3 (en) Flashmelt oral dosage formulation
IL165069A0 (en) Immediate release pharmaceutical formulation
GB2388541B (en) Aerosol formulations containing a particulate active substance
AU2002340573A8 (en) Powdery active ingredient formulations
PL1848439T3 (pl) Doustna formulacja o natychmiastowym uwalnianiu słabo rozpuszczalnej w wodzie substancji aktywnej
AU2003295846A8 (en) Pharmaceutical formulations of celcoxib
GB0225926D0 (en) Pharmaceutical paste formulations
IL183554A0 (en) Oral immediate formulation of a poorly watersoluble active substance
ZA200705021B (en) Oral immediate release formulation of a poorly water-soluble active substance
HK1091120A1 (en) Method of preparing a formulation containing a microdosed active principle
AU2002339720A1 (en) Improved pharmaceutical dental formulations
GB0225702D0 (en) Oral formulation of moisutre-sensitive drugs
AU2001283438A1 (en) A method of stabilizing a dry powder pharmaceutical formulation
HRP20040757A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120211